NCT02213289View on ClinicalTrials.gov

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 20, 2015

Primary Completion Date

February 1, 2020

Study Completion Date

August 20, 2020

Conditions
Adenocarcinoma
Interventions
DRUG

Trastuzumab

Trastuzumab

DRUG

ABT-806

ABT-806

DRUG

Bemarituzumab

Bemarituzumab

DRUG

Ramucirumab

Ramucirumab

DRUG

Nivolumab

Nivolumab

DRUG

Standard cytotherapy

FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

University of Chicago

OTHER